Cool Japan Fund Inc.

Overview / Policy implications

Spiber, a biotech venture company launched out of the Keio University Institute for Advanced Biosciences in 2007, engages in the development and production of synthetic proteins based on engineered spider silk DNA. Funds raised from this round, in which Cool Japan Fund was the lead investor, will be used to propel Spiber’s transition into the commercialization phase.

The funds will be utilized for the planned construction of the company’s first mass-production plant, to be located in Thailand. Cool Japan Fund aims to increase global awareness of Japan’s cutting-edge material and fiber development manufacturing initiatives and cultivate new demand in the international fashion and apparel markets.